Champions Oncology, Inc. (CSBR)

Over the past six months, Champions Oncology's stock price has experienced fluctuations, falling by -10.17% and by -39.83% over the last year. Key events include the Q2 FY2026 financial results, where the company reported record quarterly service revenue of $15.0 million, up 11.5% year-over-year. Q3 FY2026 financial results showed total revenue of $16.6 million, a decrease of approximately 3% from the prior year, but core study revenue reached a record $16.6 million, representing approximately 32% growth year-over-year. Rob Brainin was appointed as the new CEO. The company launched a radiopharmaceutical services platform and entered into a strategic collaboration to integrate its multi-omic datasets with an external virtual cell simulation platform. Brian Alexander was named to the board.

The provided search results do not contain explicit information about the demand seasonality for Champions Oncology, Inc.'s products and services. However, the company's revenue is primarily derived from research services, and its performance can be sensitive to client R&D spending. While quarterly revenue can fluctuate, the underlying demand for its services has been described as healthy, with a focus on expanding the pipeline of future work.

Champions Oncology, Inc. is a technology-enabled research company specializing in oncology solutions for drug discovery and development, operating within the Healthcare sector. Its core business revolves around its TumorGraft technology platform, which involves implanting human tumors into immune-deficient mice to create "mouse avatars" for testing cancer therapies. The company also offers translational oncology solutions, including Lumin Bioinformatics, and preclinical and clinical specialty testing services.

Champions Oncology, Inc. is headquartered in Hackensack, New Jersey, United States. The company supports studies globally with clinical sites, laboratories, and a scientific team strategically distributed around the world. TumorGrafts are procured through agreements with institutions in the U.S. and overseas.

Champions Oncology emphasizes its dedication to scientific excellence and corporate citizenship. The company prides itself on providing high-quality data and accelerating oncology research through end-to-end research and development solutions. The company has highlighted its pivot to profitability in fiscal year 2025, reporting record annual revenue of $57 million and a significant turnaround to positive Adjusted EBITDA of $7.1 million. The launch of its high-margin data business has also been a positive development for its market position. No specific negative events significantly impacting Champions Oncology's brand reputation in the past year were found in the search results.

Champions Oncology, Inc. stock ownership is a mix of institutional, insider, and retail investors. Institutional investors own approximately 32.87% to 41.30% of the stock, with major shareholders including Vanguard Group Inc. and Tocqueville Asset Management L.P. Insiders hold a notably high stake, ranging up to 46.98% of the company, with Michael Maurice Brown being the largest individual shareholder. Retail investors hold a substantial portion, around 46.97% of the stock.